Poly PharmacyAMIDA-ICHNCT07015112
Applying a Multidisciplinary Intervention for Drug Adequacy in an Intermediate Care Hospital (AMIDA-ICH)
A study testing Patient-centered multidisciplinary treatment review in people with Poly Pharmacy and Frail Elderly, run by Parc Sanitari Pere Virgili at 1 site in Spain.
Trial summary
The goal of this clinical trial is to learn if a multi-professional (conducted by geriatricians, clinical pharmacists, nurses) medication revision, centered on patients' goals and characteristics, can improve treatment adequacy in older adults admitted to an intermediate care hospital. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Poly Pharmacy, Frail Elderly
- What is being tested?
- Patient-centered multidisciplinary treatment review
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteSpain
- Study dates
- 4 Jan 2024to Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- older adults (65+ years)
- ≥ 3 or more chronic conditions requiring medical therapy
- able to speak Spanish
- capacity to provide informed consent or have a surrogate able to consent on their behalf
Who cannot join
- unable to provide informed consent
- anticipated length of hospital stay < 72h
- estimated life expectancy < 3 months
- homeless
- already enrolled in a drug trial
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Parc Sanitari Pere Virgili
Barcelona, Barcelona, 08023
Ana M de Andrés Lázaro, Pharmacist, PhD, +34 93 259 41 28, amandres@perevirgili.cat
About this study
Official title: Applying a Multidisciplinary Intervention for Drug Adequacy in a Intermediate Care Hospital (AMIDA-ICH)
The goal of this clinical trial is to learn if a multi-professional (conducted by geriatricians, clinical pharmacists, nurses) medication revision, centered on patients' goals and characteristics, can improve treatment adequacy in older adults admitted to an intermediate care hospital.
The main question it aims to answer is: does this approach reduce the average number of medications taken per patient?
Read more
Researchers will compare this multi-professional patient-centered revision to the usual standard of care (treatment revision conducted by a clinical pharmacist) to see if the patient-centered revision works in improving treatment adequacy.
Participants admitted to an intermediate care hospital will undergo a comprehensive assessment by a geriatrician, and a medication revision (conducted by a multidisciplinary team or a clinical-pharmacist alone). They will also be asked to fulfill some questionnaires on their health status and attitudes. Any possible adverse events to the medications will be recorded at discharge. Participants will be contacted again three months after discharge to check for any readmission or death.
- Conditions
- Poly Pharmacy, Frail Elderly
- Being tested
- Patient-centered multidisciplinary treatment review
- Keywords
- polypharmacy, frailty, adverse drug event, deprescribing
- Medical subject headings
- Frailty, Drug-Related Side Effects and Adverse Reactions
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient-centered multidisciplinary treatment reviewOther
Patient-centered multidisciplinary treatment review is defined as a medication review conducted by a multidisciplinary team (geriatrician, clinical pharmacist, nurse) according to a patient-centered methodology, based on person-centered evaluation of both personal and clinical insights, diagnostic-centered evaluation (based on current guidelines), and drug-centered evaluation (based on adequacy)
| Study group | Role | What they receive |
|---|---|---|
| Control (usual care) | No intervention | Control arm will receive usual standard of care |
| Intervention (patient-centered medication review) | Experimental | Intervention arm will receive a multidisciplinary patient-centered medication review Receives: Other: Patient-centered multidisciplinary treatment review |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of drugs
Median number of drugs per patient
Measured: Baseline and after discharge, an average of 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2025
- Study start4 Jan 2024
- Primary completionDec 2025 (estimated)
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Poly PharmacyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Stepped-wedge
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Parc Sanitari Pere Virgili
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07015112
- Sponsor's protocol ID
- AMIDA-ICH
- Acronym
- AMIDA-ICH
- Status last verified
- Jun 2025
- First submitted
- 1 Jun 2025
- Last updated
- 11 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Salis F, Soler-Blanco N, Molist-Brunet N, Gual-Tarrada N, Ribera A, Cherubini A, Inzitari M, de Andres-Lazaro AM. Applying a multidisciplinary intervention for drug adequacy in an intermediate care hospital (AMIDA-ICH): study protocol of a complex intervention trial. Front Med (Lausanne). 2026 Aug 19;13:1857969. doi: 10.3389/fmed.2026.1857969. eCollection 2026.
PubMed 42688749
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Applying a Multidisciplinary Intervention for Drug Adequacy in a Intermediate Care Hospital (AMIDA-ICH)
- ClinicalTrials.gov ID
- NCT07015112
- Acronym / sponsor ID
- AMIDA-ICH / AMIDA-ICH
- Conditions
- Poly Pharmacy, Frail Elderly
- Keywords
- polypharmacy, frailty, adverse drug event, deprescribing
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Parc Sanitari Pere VirgiliUniversity, hospital or other
- Study start
- 4 Jan 2024 (actual)
- Primary completion
- Dec 2025 (estimated)
- Study completion
- Jun 2026 (estimated)
- First posted
- 11 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if a multi-professional (conducted by geriatricians, clinical pharmacists, nurses) medication revision, centered on patients' goals and characteristics, can improve treatment adequacy in older adults admitted to an intermediate care hospital.
The main question it aims to answer is: does this approach reduce the average number of medications taken per patient?
Researchers will compare this multi-professional patient-centered revision to the usual standard of care (treatment revision conducted by a clinical pharmacist) to see if the patient-centered revision works in improving treatment adequacy.
Participants admitted to an intermediate care hospital will undergo a comprehensive assessment by a geriatrician, and a medication revision (conducted by a multidisciplinary team or a clinical-pharmacist alone). They will also be asked to fulfill some questionnaires on their health status and attitudes. Any possible adverse events to the medications will be recorded at discharge. Participants will be contacted again three months after discharge to check for any readmission or death.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Stepped-wedge
| Arm | Type | Receives |
|---|---|---|
| Control (usual care) | No intervention | –Control arm will receive usual standard of care |
| Intervention (patient-centered medication review) | Experimental | Other: Patient-centered multidisciplinary treatment reviewIntervention arm will receive a multidisciplinary patient-centered medication review |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (4 listed)
- older adults (65+ years)
- ≥ 3 or more chronic conditions requiring medical therapy
- able to speak Spanish
- capacity to provide informed consent or have a surrogate able to consent on their behalf
Key exclusion criteria (5 listed)
- unable to provide informed consent
- anticipated length of hospital stay < 72h
- estimated life expectancy < 3 months
- homeless
- already enrolled in a drug trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patient-centered multidisciplinary treatment reviewPatient-centered multidisciplinary treatment review is defined as a medication review conducted by a multidisciplinary team (geriatrician, clinical pharmacist, nurse) according to a patient-centered methodology, based on person-centered evaluation of both personal and clinical insights, diagnostic-centered evaluation (based on current guidelines), and drug-centered evaluation (based on adequacy) | Other | Intervention (patient-centered medication review) |
Primary outcome
Number of drugs
Time frame: Baseline and after discharge, an average of 30 days
Median number of drugs per patient
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2025.
- Derived from this study: PubMed 42688749Salis F, Soler-Blanco N, Molist-Brunet N, Gual-Tarrada N, Ribera A, Cherubini A, Inzitari M, de Andres-Lazaro AM. Applying a multidisciplinary intervention for drug adequacy in an intermediate care hospital (AMIDA-ICH): study protocol of a complex intervention trial. Front Med (Lausanne). 2026 Aug 19;13:1857969. doi: 10.3389/fmed.2026.1857969. eCollection 2026.
Related trials for Poly Pharmacy
Active, not recruiting
Itaca App vs. Usual Care for Medication Adherence in Older Adults on Polypharmacy
Medication Adherence, Poly Pharmacy
Recruiting
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
Fall, Fall Accident
RecruitingObservational study
Interprofessional Pharmacogenomics (IPGx) Registry and Repository
Diabetes, Cholesterol
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Patient-centered multidisciplinary treatment review in people with Poly Pharmacy and Frail Elderly, run by Parc Sanitari Pere Virgili at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ana M de Andrés Lázaro, Pharmacist. PhD (+34932594128, amandres@perevirgili.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of drugs (time frame: Baseline and after discharge, an average of 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07015112, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2025.